Bormioli Pharma, a leading international manufacturer of pharmaceutical packaging and medical devices, today announced a significant increase of 47% in its North American sales for 2023. This notable growth is a direct result of the company’s rapidly evolving infrastructure and expanded capacity, tailored to meet the unique demands of the North American pharmaceutical market, including an increased need for pharmaceutical glass vials.
Bormioli Pharma strengthened its strategic focus on the US market four years ago by establishing a new legal entity and a commercial branch in the US. From then on, the company’s on-site commercial team has been expanded, an FDA-approved warehouse established, and dedicated product offerings compatible with regional standards have been designed. For North American customers, this translates into the availability of a reliable and flexible packaging partner that can streamline their purchasing processes while reducing supply chain complexity, shortening their time-to-market and supporting them in the development of high-value projects with local, qualified support.
The pharmaceutical glass vials market is projected to grow from $12.1bn in 2023 to $24.1bn by 2033, expanding at a 7.10% combined annual growth rate (CAGR), driven by rising pharmaceutical product demands. The US market is one of the major growth contributors (with an expected CAGR of 8.0% in North America for 2023-2028) and there is a high demand for suppliers capable of providing turn-key packaging solutions that meet regional standards, such as the use of glass Type I expansion 33. Bormioli Pharma recently signed a key contract with a US-based global leader in allergen immunotherapy for the supply of ready-to-use, vertically integrated packaging kits for two of its major manufacturing sites in the US. The full packaging kits include aluminium seals, rubber stoppers, Type I molded glass vials, and Type I tubular glass expansion 33 vials.
“As we grow our presence in North America and expand our capabilities to meet regional standards, we are committed to the partnerships that enable us to broaden our reach,” said Johann Depperschmidt, Bormioli Pharma’s Head of Sales, Americas. “To best serve our North American customers, we’ve adapted our manufacturing processes to produce Type I Glass expansion 33 vials in our European facilities, ensuring robust production and backup. We have an on-site, dedicated US sales team and a local warehouse, and we look forward to expanding these resources further in 2024. Additionally, we are collaborating with a US-based sterilisation company to prepare ready-to-use packaging kits – a partnership we believe is a significant step forward in ensuring that quality healthcare becomes a more accessible reality for people everywhere.”
Bormioli Pharma’s chief executive officer, Andrea Lodetti, noted: “Our momentous growth in the North American market embodies our dedication to meeting and exceeding the evolving needs of this dynamic market. We are not just expanding our footprint but also enhancing our efficiency and adaptability. This growth aligns perfectly with our mission to provide innovative and sustainable pharmaceutical packaging solutions, and we are proud to say that our growth is not only robust but also responsible.”
Bormioli Pharma has committed to several initiatives that place the company at the forefront of sustainable pharma packaging. The company has embarked on a strong environmental, social and governance (ESG) path and is working to publish its third ESG Report later this year. Bormioli Pharma made notable progress in its ’50-in-5′ programme, which aims to achieve 50% of sustainable raw materials in its sold pharmaceutical packaging products by 2025. In 2023, the company successfully increased its use of sustainable raw materials to 45%, up from 39% in the previous year. Additionally, it conducted comprehensive analyses on its sustainable pharma packaging, reaffirming the uncompromised safety and reliability of its products. Furthermore, Bormioli Pharma recently collaborated with Loop Industries, a leading Canadian technology company, to develop an innovative and sustainable pharmaceutical packaging solution manufactured with 100% recycled virgin quality Loop™ PET resin.
To learn more about Bormioli Pharma’s comprehensive packaging solutions and sustainability initiatives, please see Bormioli executives at DCAT Week 2024 in New York City (18-21 March) or contact dcat@bormiolipharma.com.